MedTrace Logo

Follow-up Study to Previous CARE Trial

NCT00479024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 294

Last updated 2009-09-30

No results posted yet for this study

Summary

To determine comparative 1-year outcomes in renally impaired patients who previously underwent cardiac angiography with Isovue®-370 or Visipaque™ 320 as part of the IOP-104 trial protocol and were evaluable for determination of post-contrast significant renal injury (defined as \>25% increase in SCr or \>25% increase in cystatin C).

Conditions

  • Moderate to Severe Chronic Kidney Disease

Interventions

DRUG

iodinated contrast agent

iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Steven Sireci, M.D. · Bracco Diagnostics, Inc

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479024 on ClinicalTrials.gov